 - Report: Mass. outperforms other states in biopharma employment
A report by MassBio showed that the biopharmaceutical industry in Massachusetts employed 48,000 workers in 2010, and biotech firms in the state obtained 23% of all U.S. venture capital funding last year. The report also revealed that 40% of 900 experimental drugs being developed by the state's biotech firms are focused on the treatment of cancer. Mass High Tech (Boston) (9/27)        | With in-depth industry experience and expertise, GE Capital, Healthcare Financial Services’ dedicated Life Science Finance team has worked with more than 500 companies and provided over $2.5 billion in financing to the market. Click here to find out more and take our online poll. | - GE Healthcare's R&D exec has high hopes for stem cells
Stephen Minger, GE Healthcare's global research and development head for cell technologies, said the companies' interest in investing in stem cells and regenerative medicine "suggests a level of maturity" and that the FDA and drugmakers should use stem cell models to accurately determine the adverse effects of drugs. Minger said he believes that there would be a vast supply of stem cells in the world for use in disease treatment if China and India direct even 1% of their annual births to public cord-blood banks. Forbes (9/26) - Experts discover gene "hypermutations" in advanced prostate cancers
U.S. researchers said they have sequenced the genome of advanced prostate cancers and found that certain aggressive tumor types have genetic hypermutations, or DNA errors that allow tumors to resist treatments. The findings in the Proceedings of the National Academy of Sciences could provide clues as to why some prostate cancers are more likely to be fatal and help improve the development of tests and drugs for the disease, said one of the authors of the study. HealthDay News (9/27)  - Jackson Laboratory gets NIH grant for genome database
The NIH has awarded a $24.6 million grant to Jackson Laboratory to help it continue gathering data for its Mouse Genome Database, which contains genetic data on laboratory mice used by scientists in conducting research into cancer and other human conditions. The laboratory also will use the five-year grant to make the open-source database more user-friendly. Furthermore, the funding will help to maintain jobs in Maine, said Joyce Peterson, a spokeswoman for the laboratory. Bangor Daily News (Maine) (free registration) (9/27) - Tarix secures orphan-drug status for peptide drug candidate
Tarix Pharmaceuticals received orphan-drug designation from the FDA to use experimental peptide drug TXA127 in patients with pulmonary arterial hypertension. In June 2010, the company obtained the same status for the drug as treatment for myelodysplastic syndromes and engraftment of people undergoing a stem cell transplant. Mass High Tech (Boston) (9/27) - Susan G. Komen Foundation grants $3.5M for collaborative study
Researchers at the Translational Genomics Research Institute, the Karmanos Cancer Institute and the University of Michigan Comprehensive Cancer Center will use $3.5 million from the Susan G. Komen Foundation to study triple-negative breast cancer in African and African-American women and translate their discoveries into clinical practice. Researchers at Baylor College of Medicine in Houston and the Van Andel Research Institute will also participate in the studies. GenomeWeb Daily News (9/26) - NHGRI awards $5.7M for ethics in genomics study
Seven researchers will study the question of whether participants in genomics studies should be informed of any risks for diseases or conditions that scientists discover when researching their genomes. "These new research projects will help us understand how people are reacting to real information about their genomes, which is an increasingly pressing issue as more scientists incorporate genome sequencing into their research," said National Human Genome Research Institute Director Eric Green. GenomeWeb Daily News (9/26) 
| Industrial & Environmental |  |  | | - Firm using "supercritical" water to release sugars from biomass
Renmatix is opening a research-and-development facility in King of Prussia, Pa., to continue development of a technology that uses pressurized hot water to harvest fermentable sugars from cellulosic biomass. Putting water in the so-called "supercritical phase" could make it act like an acid, the company said. "We use no significant consumables, like enzymes or acids," said Fred Moesler, a Renmatix engineer who is in charge of increasing the scale of the process. The New York Times (tiered subscription model) (9/27)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | He who postpones the hour of living rightly is like the rustic who waits for the river to run out before he crosses."
|
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, September 27, 2011
- Monday, September 26, 2011
- Friday, September 23, 2011
- Thursday, September 22, 2011
- Wednesday, September 21, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment